fashion -WSS

fashion

author：knowledge 2025-09-03 14:39:35 - browse：8258

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed. Joe Raedle/Getty Images

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed, per reports from Bloomberg.

Experts largely hailed the rumored sale as a good buy, citing the management of chronic conditions in the Medicare Advantage population through primary care, ChenMed’s specialty, as an area with huge innovation and cost savings over the last 10 years.

“If you’re going to purchase primary care in the senior space, there’s no one better than ChenMed. The only other one that might be better or equivalent would be Oak Street, but they were just purchased,” said Jon Kaplan, a senior partner at BCG. “In the world of great primary care practices to buy, in my top two are Oak Street and ChenMed, and one of them’s available, one’s not.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： ActiGraph execs on goal of drug approvals with digital endpoints

WSS

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Evacuations in place as 3 wildfires burn in eastern Washington state

Anthos stroke drug appears safer than common blood thinner

FDA's Woodcock to retire early next year

Wegovy, Zepbound and weight loss drugs that preserve muscle

Liz Cheney makes 1st public comment since Trump's election interference indictments

knowledge

fashion

focus

As demand for Covid shots wanes, Moderna seeks its next success

CRISPR pioneers react to Casgevy, first gene

Virginia high school admissions case could be legal follow

Hilary expected to bring catastrophic, life

How to save PrEP access — and even expand it

NYU radiologists take on the challenge of expensive MRI machines

Malaria cases in Florida and Texas: Here’s what you need to know

Lung cancer is America's deadliest cancer. Yet so few get screened

Duchenne breakthrough therapy leaves behind pioneering families

Clinical trials must include more disabled people

knowledge

David Sabatini, ex

ProMED sees offers of support, but its future remains unclear

In key trial, Verve's treatment lowers cholesterol levels in patients

Evacuations in place as 3 wildfires burn in eastern Washington state

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

PBM reforms clear House panel

focus

knowledge

knowledge

hotspot